Literature DB >> 29903758

Pitfalls in the molecular follow up of NPM1 mutant acute myeloid leukemia.

Ulrike Bacher1,2, Naomi Porret1, Raphael Joncourt1, Javier Sanz3, Nijas Aliu3, Gertrud Wiedemann1, Barbara Jeker4, Yara Banz5, Thomas Pabst6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29903758      PMCID： PMC6165800          DOI： 10.3324/haematol.2018.192104

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years.

Authors:  Alexander D Heini; Martin D Berger; Katja Seipel; Behrouz Mansouri Taleghani; Gabriela M Baerlocher; Kurt Leibundgut; Yara Banz; Urban Novak; Thomas Pabst
Journal:  Leuk Res       Date:  2016-12-08       Impact factor: 3.156

2.  Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Tomasz Czerw; Myriam Labopin; Norbert-Claude Gorin; Sebastian Giebel; Didier Blaise; Giovanna Meloni; Arnaud Pigneux; Alberto Bosi; Joan Veelken; Felicetto Ferrara; Nicolaas Schaap; Roberto M Lemoli; Jan J Cornelissen; Eric Beohou; Arnon Nagler; Mohamad Mohty
Journal:  Cancer       Date:  2016-03-28       Impact factor: 6.860

3.  Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.

Authors:  Nuria Mencia-Trinchant; Yang Hu; Maria Antonina Alas; Fatima Ali; Bas J Wouters; Sangmin Lee; Ellen K Ritchie; Pinkal Desai; Monica L Guzman; Gail J Roboz; Duane C Hassane
Journal:  J Mol Diagn       Date:  2017-05-16       Impact factor: 5.568

4.  Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

Authors:  Jan Krönke; Richard F Schlenk; Kai-Ole Jensen; Florian Tschürtz; Andrea Corbacioglu; Verena I Gaidzik; Peter Paschka; Shiva Onken; Karina Eiwen; Marianne Habdank; Daniela Späth; Michael Lübbert; Mohammed Wattad; Thomas Kindler; Helmut R Salih; Gerhard Held; David Nachbaur; Marie von Lilienfeld-Toal; Ulrich Germing; Detlef Haase; Hans-Günther Mergenthaler; Jürgen Krauter; Arnold Ganser; Gudrun Göhring; Brigitte Schlegelberger; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

5.  Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.

Authors:  Jan Krönke; Lars Bullinger; Veronica Teleanu; Florian Tschürtz; Verena I Gaidzik; Michael W M Kühn; Frank G Rücker; Karlheinz Holzmann; Peter Paschka; Silke Kapp-Schwörer; Daniela Späth; Thomas Kindler; Marcus Schittenhelm; Jürgen Krauter; Arnold Ganser; Gudrun Göhring; Brigitte Schlegelberger; Richard F Schlenk; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

6.  Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.

Authors:  P Gorello; G Cazzaniga; F Alberti; M G Dell'Oro; E Gottardi; G Specchia; G Roti; R Rosati; M F Martelli; D Diverio; F Lo Coco; A Biondi; G Saglio; C Mecucci; B Falini
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

7.  Molecular Minimal Residual Disease in Acute Myeloid Leukemia.

Authors:  Mojca Jongen-Lavrencic; Tim Grob; Diana Hanekamp; François G Kavelaars; Adil Al Hinai; Annelieke Zeilemaker; Claudia A J Erpelinck-Verschueren; Patrycja L Gradowska; Rosa Meijer; Jacqueline Cloos; Bart J Biemond; Carlos Graux; Marinus van Marwijk Kooy; Markus G Manz; Thomas Pabst; Jakob R Passweg; Violaine Havelange; Gert J Ossenkoppele; Mathijs A Sanders; Gerrit J Schuurhuis; Bob Löwenberg; Peter J M Valk
Journal:  N Engl J Med       Date:  2018-03-29       Impact factor: 91.245

8.  Assessment of Minimal Residual Disease in Standard-Risk AML.

Authors:  Adam Ivey; Robert K Hills; Michael A Simpson; Jelena V Jovanovic; Amanda Gilkes; Angela Grech; Yashma Patel; Neesa Bhudia; Hassan Farah; Joanne Mason; Kerry Wall; Susanna Akiki; Michael Griffiths; Ellen Solomon; Frank McCaughan; David C Linch; Rosemary E Gale; Paresh Vyas; Sylvie D Freeman; Nigel Russell; Alan K Burnett; David Grimwade
Journal:  N Engl J Med       Date:  2016-01-20       Impact factor: 91.245

9.  Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?

Authors:  G Webersinke; W Kranewitter; S Deutschbauer; O Zach; S Hasenschwandtner; K Wiesinger; M Erdel; R Marschon; A Böhm; G Tschurtschenthaler
Journal:  Blood Cancer J       Date:  2014-06-27       Impact factor: 11.037

10.  Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.

Authors:  Stephen J Salipante; Jonathan R Fromm; Jay Shendure; Brent L Wood; David Wu
Journal:  Mod Pathol       Date:  2014-04-18       Impact factor: 7.842
View more
  6 in total

1.  Molecular minimal residual disease negativity and decreased stem cell mobilization potential predict excellent outcome after autologous transplant in NPM1 mutant acute myeloid leukemia.

Authors:  Alvaro de Santiago de Benito; Barbara Jeker; Eva Gfeller; Naomi Porret; Yara Banz; Urban Novak; Ulrike Bacher; Thomas Pabst
Journal:  Haematologica       Date:  2019-05-23       Impact factor: 9.941

2.  Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.

Authors:  Fei Yang; Tauangtham Anekpuritanang; Richard D Press
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

Review 3.  Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.

Authors:  Ulrike Bacher; Evgenii Shumilov; Johanna Flach; Naomi Porret; Raphael Joncourt; Gertrud Wiedemann; Martin Fiedler; Urban Novak; Ursula Amstutz; Thomas Pabst
Journal:  Blood Cancer J       Date:  2018-11-12       Impact factor: 11.037

Review 4.  Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.

Authors:  Fabio Forghieri; Patrizia Comoli; Roberto Marasca; Leonardo Potenza; Mario Luppi
Journal:  Int J Mol Sci       Date:  2018-11-06       Impact factor: 5.923

5.  Experiences with Next-Generation Sequencing in Relapsed Acute Myeloid Leukemia: A Patient Case Series.

Authors:  Johanna Flach; Evgenii Shumilov; Naomi Porret; Inna Shakhanova; Myriam Legros; Marie-Noëlle Kronig; Raphael Joncourt; Ulrike Bacher; Thomas Pabst
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-09-01       Impact factor: 2.576

Review 6.  The Role of Nucleophosmin 1 (NPM1) Mutation in the Diagnosis and Management of Myeloid Neoplasms.

Authors:  Katalin Kelemen
Journal:  Life (Basel)       Date:  2022-01-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.